Inhibitors of 7-Dehydrocholesterol Reductase: Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells

Hye Young H Kim, Z. Korade, Keri A. Tallman, Wei Liu, C. David Weaver, K. Mirnics, Ned A. Porter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A small library of pharmacologically active compounds (the NIH Clinical Collection) was assayed in Neuro2a cells to determine their effect on the last step in the biosynthesis of cholesterol, the transformation of 7-dehydrocholesterol (7-DHC) to cholesterol promoted by 7-dehydrocholesterol reductase, DHCR7. Of some 727 compounds in the NIH Clinical Collection, over 30 compounds significantly increased 7-DHC in Neuro2a cells when assayed at 1 μM. Active compounds that increased 7-DHC with a Z-score of +3 or greater generally gave rise to modest decreases in desmosterol and increases in lanosterol levels. Among the most active compounds identified in the library were the antipsychotic, antidepressant, and anxiolytic compounds that included perospirone, nefazodone, haloperidol, aripiprazole, trazodone, and buspirone. Fluoxetine and risperidone were also active at 1 μM, and another 10 compounds in this class of pharmaceuticals were identified in the screen at concentrations of 10 μM. Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human condition that results from a mutation in the gene that encodes DHCR7. The SLOS phenotype includes neurological deficits and congenital malformations, and it is linked to a higher incidence of autism spectrum disorder. The significance of the current study is that it identifies common pharmacological compounds that may induce a biochemical presentation similar to SLOS. Little is known about the side effects of elevated 7-DHC postdevelopmentally, and the elevated 7-DHC that results from exposure to these compounds may also be a confounder in the diagnosis of SLOS.

Original languageEnglish
Pages (from-to)892-900
Number of pages9
JournalChemical Research in Toxicology
Volume29
Issue number5
DOIs
Publication statusPublished - May 16 2016

Fingerprint

Smith-Lemli-Opitz Syndrome
Screening
Desmosterol
Cholesterol
Lanosterol
Trazodone
Buspirone
Risperidone
Fluoxetine
Biosynthesis
Anti-Anxiety Agents
Haloperidol
Antidepressive Agents
Antipsychotic Agents
Libraries
7-dehydrocholesterol reductase
7-dehydrocholesterol
Genes
Pharmacology
Phenotype

ASJC Scopus subject areas

  • Toxicology

Cite this

Inhibitors of 7-Dehydrocholesterol Reductase : Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells. / Kim, Hye Young H; Korade, Z.; Tallman, Keri A.; Liu, Wei; Weaver, C. David; Mirnics, K.; Porter, Ned A.

In: Chemical Research in Toxicology, Vol. 29, No. 5, 16.05.2016, p. 892-900.

Research output: Contribution to journalArticle

Kim, Hye Young H ; Korade, Z. ; Tallman, Keri A. ; Liu, Wei ; Weaver, C. David ; Mirnics, K. ; Porter, Ned A. / Inhibitors of 7-Dehydrocholesterol Reductase : Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells. In: Chemical Research in Toxicology. 2016 ; Vol. 29, No. 5. pp. 892-900.
@article{6288fe38659a48ceaba4ff7268fbf2d1,
title = "Inhibitors of 7-Dehydrocholesterol Reductase: Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells",
abstract = "A small library of pharmacologically active compounds (the NIH Clinical Collection) was assayed in Neuro2a cells to determine their effect on the last step in the biosynthesis of cholesterol, the transformation of 7-dehydrocholesterol (7-DHC) to cholesterol promoted by 7-dehydrocholesterol reductase, DHCR7. Of some 727 compounds in the NIH Clinical Collection, over 30 compounds significantly increased 7-DHC in Neuro2a cells when assayed at 1 μM. Active compounds that increased 7-DHC with a Z-score of +3 or greater generally gave rise to modest decreases in desmosterol and increases in lanosterol levels. Among the most active compounds identified in the library were the antipsychotic, antidepressant, and anxiolytic compounds that included perospirone, nefazodone, haloperidol, aripiprazole, trazodone, and buspirone. Fluoxetine and risperidone were also active at 1 μM, and another 10 compounds in this class of pharmaceuticals were identified in the screen at concentrations of 10 μM. Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human condition that results from a mutation in the gene that encodes DHCR7. The SLOS phenotype includes neurological deficits and congenital malformations, and it is linked to a higher incidence of autism spectrum disorder. The significance of the current study is that it identifies common pharmacological compounds that may induce a biochemical presentation similar to SLOS. Little is known about the side effects of elevated 7-DHC postdevelopmentally, and the elevated 7-DHC that results from exposure to these compounds may also be a confounder in the diagnosis of SLOS.",
author = "Kim, {Hye Young H} and Z. Korade and Tallman, {Keri A.} and Wei Liu and Weaver, {C. David} and K. Mirnics and Porter, {Ned A.}",
year = "2016",
month = "5",
day = "16",
doi = "10.1021/acs.chemrestox.6b00054",
language = "English",
volume = "29",
pages = "892--900",
journal = "Chemical Research in Toxicology",
issn = "0893-228X",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Inhibitors of 7-Dehydrocholesterol Reductase

T2 - Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells

AU - Kim, Hye Young H

AU - Korade, Z.

AU - Tallman, Keri A.

AU - Liu, Wei

AU - Weaver, C. David

AU - Mirnics, K.

AU - Porter, Ned A.

PY - 2016/5/16

Y1 - 2016/5/16

N2 - A small library of pharmacologically active compounds (the NIH Clinical Collection) was assayed in Neuro2a cells to determine their effect on the last step in the biosynthesis of cholesterol, the transformation of 7-dehydrocholesterol (7-DHC) to cholesterol promoted by 7-dehydrocholesterol reductase, DHCR7. Of some 727 compounds in the NIH Clinical Collection, over 30 compounds significantly increased 7-DHC in Neuro2a cells when assayed at 1 μM. Active compounds that increased 7-DHC with a Z-score of +3 or greater generally gave rise to modest decreases in desmosterol and increases in lanosterol levels. Among the most active compounds identified in the library were the antipsychotic, antidepressant, and anxiolytic compounds that included perospirone, nefazodone, haloperidol, aripiprazole, trazodone, and buspirone. Fluoxetine and risperidone were also active at 1 μM, and another 10 compounds in this class of pharmaceuticals were identified in the screen at concentrations of 10 μM. Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human condition that results from a mutation in the gene that encodes DHCR7. The SLOS phenotype includes neurological deficits and congenital malformations, and it is linked to a higher incidence of autism spectrum disorder. The significance of the current study is that it identifies common pharmacological compounds that may induce a biochemical presentation similar to SLOS. Little is known about the side effects of elevated 7-DHC postdevelopmentally, and the elevated 7-DHC that results from exposure to these compounds may also be a confounder in the diagnosis of SLOS.

AB - A small library of pharmacologically active compounds (the NIH Clinical Collection) was assayed in Neuro2a cells to determine their effect on the last step in the biosynthesis of cholesterol, the transformation of 7-dehydrocholesterol (7-DHC) to cholesterol promoted by 7-dehydrocholesterol reductase, DHCR7. Of some 727 compounds in the NIH Clinical Collection, over 30 compounds significantly increased 7-DHC in Neuro2a cells when assayed at 1 μM. Active compounds that increased 7-DHC with a Z-score of +3 or greater generally gave rise to modest decreases in desmosterol and increases in lanosterol levels. Among the most active compounds identified in the library were the antipsychotic, antidepressant, and anxiolytic compounds that included perospirone, nefazodone, haloperidol, aripiprazole, trazodone, and buspirone. Fluoxetine and risperidone were also active at 1 μM, and another 10 compounds in this class of pharmaceuticals were identified in the screen at concentrations of 10 μM. Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human condition that results from a mutation in the gene that encodes DHCR7. The SLOS phenotype includes neurological deficits and congenital malformations, and it is linked to a higher incidence of autism spectrum disorder. The significance of the current study is that it identifies common pharmacological compounds that may induce a biochemical presentation similar to SLOS. Little is known about the side effects of elevated 7-DHC postdevelopmentally, and the elevated 7-DHC that results from exposure to these compounds may also be a confounder in the diagnosis of SLOS.

UR - http://www.scopus.com/inward/record.url?scp=84969785589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969785589&partnerID=8YFLogxK

U2 - 10.1021/acs.chemrestox.6b00054

DO - 10.1021/acs.chemrestox.6b00054

M3 - Article

C2 - 27097157

AN - SCOPUS:84969785589

VL - 29

SP - 892

EP - 900

JO - Chemical Research in Toxicology

JF - Chemical Research in Toxicology

SN - 0893-228X

IS - 5

ER -